Global Patent Index - EP 1079688 A1

EP 1079688 A1 2001-03-07 - METHOD FOR EXPANDING PRIMATE B CELLS SELECTIVELY IN IMMUNOCOMPROMISED MICE AND PRODUCING LARGE NUMBERS OF ANTIGEN-SPECIFIC B LYMPHOCYTES FOR THE PRODUCTION OF PRIMATE MONOCLONAL ANTIBODIES

Title (en)

METHOD FOR EXPANDING PRIMATE B CELLS SELECTIVELY IN IMMUNOCOMPROMISED MICE AND PRODUCING LARGE NUMBERS OF ANTIGEN-SPECIFIC B LYMPHOCYTES FOR THE PRODUCTION OF PRIMATE MONOCLONAL ANTIBODIES

Title (de)

VERFAHREN ZUR EXPANSION VON PRIMAT B-ZELLEN SELEKTIV IN IMMUNITÄTSBEEINSTRÄCHTIGTEN MÄUSE UND PRODUKTION VON HOHER ANZAHL AN ANTIGENSPEZIFISCHE B-LYMPHOZYTEN FÜR DIE PRODUKTION VON PRIMAT MONOKLONALE ANTIKÖRPER

Title (fr)

PROCEDE PERMETTANT D'AUGMENTER DES LYMPHOCYTES B DE PRIMATES CHEZ LA SOURIS IMMUNODEPRIMEE, ET DE PRODUIRE DE GRANDS NOMBRES DE LYMPHOCYTES B SPECIFIQUES DE L'ANTIGENE POUR LA PRODUCTION D'ANTICORPS MONOCLONAUX DE PRIMATES

Publication

EP 1079688 A1 (EN)

Application

EP 99926411 A

Priority

  • EP 99926411 A
  • EP 9903605 W
  • EP 98870121 A

Abstract (en)

[origin: WO9960846A1] The present invention relates to a method for reconstituting immunocompromised mice with primate cells, consisting of the following steps: (a) preparation of an immunocompromised mouse by administration of an antibody against the beta chain of the mouse interleukin 2 (IL-2) receptor, more particularly the monoclonal mouse TM- beta 1 monoclonal antibody and/or gamma irradiation, (b) intraspleen injection of primate cells into the spleen of the pre-treated immunocompromised mouse of step (a), where these primate cells preferably originate from a primate donor and where this primate donor may have been immunised with a well-defined antigen. This method was found to be highly suitable for expanding primate B lymphocytes in an animal model in a rapid, as yet unequalled manner. Other embodiments of this invention relate to immunocompromised mice obtained by the aforesaid method and also the use thereof as animal models, primate B cell culture produced and primate monoclonal antibodies derived therefrom.

IPC 1-7 (main, further and additional classification)

A01K 67/027; C12N 5/28; C12P 21/08

IPC 8 full level (invention and additional information)

A01K 67/027 (2006.01); C07K 16/08 (2006.01); C07K 16/10 (2006.01); C07K 16/24 (2006.01); C12N 5/20 (2006.01); C12N 5/28 (2006.01); C12P 21/08 (2006.01); A61K 35/12 (2006.01)

CPC (invention and additional information)

A01K 67/0271 (2013.01); C07K 16/082 (2013.01); C07K 16/109 (2013.01); C07K 16/246 (2013.01); A61K 2035/124 (2013.01); C12N 2517/02 (2013.01)

Citation (search report)

See references of WO 9960846A1

Designated contracting state (EPC)

AT BE CH CY DE DK ES FI FR GB GR IE IT LI LU MC NL PT SE

EPO simple patent family

WO 9960846 A1 19991202; AU 4368199 A 19991213; AU 751647 B2 20020822; CA 2332336 A1 19991202; EP 1079688 A1 20010307

INPADOC legal status


2004-02-25 [18D] DEEMED TO BE WITHDRAWN

- Effective date: 20030813

2003-05-21 [17Q] FIRST EXAMINATION REPORT

- Effective date: 20030402

2001-04-04 [R17P] REQUEST FOR EXAMINATION FILED (CORRECTION)

- Effective date: 20001208

2001-03-07 [17P] REQUEST FOR EXAMINATION FILED

- Effective date: 20001123

2001-03-07 [AK] DESIGNATED CONTRACTING STATES:

- Kind Code of Ref Document: A1

- Designated State(s): AT BE CH CY DE DK ES FI FR GB GR IE IT LI LU MC NL PT SE

2001-03-07 [AX] REQUEST FOR EXTENSION OF THE EUROPEAN PATENT TO

- Free text: AL PAYMENT 20001208;LT PAYMENT 20001208;LV PAYMENT 20001208;MK PAYMENT 20001208;RO PAYMENT 20001208;SI PAYMENT 20001208